RD Tax Credits Matrix

R&D Tax Credits / Super-Deductions Matrix v0.1

What this file is

This file is a content skill that loads on top of cross-border-workflow-base. It maps the world's principal R&D tax incentives — credits, super-deductions, refundable cash incentives — as of mid-2025.

Tax year coverage. Current for fiscal year 2025, reflecting:

• UK merged RDEC scheme (FA 2024) for accounting periods beginning on or after 1 April 2024, replacing the small/mid-size R&D scheme with a single 20% above-the-line credit (~15% post-tax)
• UK ERIS (Enhanced R&D Intensive Support) for R&D-intensive loss-making SMEs (40%+ qualifying expenditure ratio) — 86% uplift + 14.5% credit on surrendered loss
• US §174 R&D capitalisation still in force per TCJA 2017 amendments (5-year domestic / 15-year foreign amortisation), with continued legislative pressure to restore immediate expensing
• Germany Forschungszulage raised to 35% of eligible costs for SMEs (otherwise 25%) under the Wachstumschancengesetz (March 2024); annual cap of EUR 10 million per claimant
• France CIR unchanged at 30% (up to EUR 100m of expenditure; 5% above)
• Netherlands WBSO rates and ceilings updated annually
• OECD BEPS Action 5 Modified Nexus interaction with R&D
• Pillar Two — R&D super-deductions can lower ETR below 15% and trigger top-up tax

The reviewer is the customer of this output. R&D claims face significant tax-authority scrutiny. Every output must be reviewed by a credentialed practitioner (typically R&D specialist firms or Big 4 R&D advisory) before any claim is filed.

Section 1 — Scope statement

This skill covers:

• Qualifying R&D definition — OECD Frascati Manual and country adaptations
• Eligibility tests — taxpayer type, sector, claim history
• Qualifying expenditure categories
• Benefit mechanism — credit, deduction, refundable cash, super-deduction
• Filing mechanics and audit risk
• Pillar Two interaction
• Patent box interaction (cross-reference)

This skill does NOT cover:

• Patent box / IP regime computation — see ip-patent-box-matrix.md
• Grant accounting beyond reference
• Country-specific R&D wage subsidies that are not tax credits
• Depreciation / amortisation of capitalised R&D assets — see country corporate tax skills

Section 2 — The Frascati definition of R&D

• OECD Frascati Manual (2015 edition) definition of R&D — R&D comprises creative and systematic work undertaken to increase the stock of knowledge, and to devise new applications of available knowledge. Five criteria, ALL of which must be met: 1. Novel — aimed at new findings; 2. Creative — based on original, not obvious, concepts and hypotheses; 3. Uncertain — outcome uncertain; 4. Systematic — planned and budgeted; 5. Transferable / reproducible — leads to results that could be transferred to / reproduced by others. Three types: Basic research — experimental or theoretical work without specific application; Applied research — original investigation for specific practical aim; Experimental development — systematic work using existing knowledge to produce new materials, products, processes. ([T1] OECD Frascati Manual (2015 edition))
• Local regime adoption of Frascati — Local regimes adopt Frascati with minor variations. Country-specific exclusions are common (e.g., UK excludes market research; France excludes routine quality control). ([T1])

Section 3 — Country regime matrix

3.1 Europe

Europe R&D regime matrix (Section 3.1 Europe country regime matrix)

Country	Mechanism	Headline rate	Notable
United Kingdom — Merged RDEC	Above-the-line credit	20% gross (≈15% net)	Single scheme from periods beginning 1 Apr 2024. Subcontractor restriction (no overseas R&D from 1 Apr 2024 with limited exceptions).
United Kingdom — ERIS (Enhanced R&D Intensive Support)	SME loss surrender	86% uplift + 14.5% credit	Loss-making SMEs with ≥30% (reduced from 40% by FA(No.2) 2024) qualifying R&D expenditure ratio.
France — CIR	Refundable credit (4-year carryforward, refund if not used)	30% of qualifying expenditure to EUR 100m; 5% above	Two-fold uplift for young innovative companies; doubling possible for grad-students hired.
France — CII (Crédit d'Impôt Innovation)	Credit	30% of qualifying innovation expenditure to EUR 400k	For SMEs; covers innovation prototyping (not pure R&D). Extended through 2027.
France — JEI / JEU	Combined tax + social contribution exemption	Up to 100% CIT exemption first year; 50% second year	Young Innovative Enterprises < 8 years old, R&D-intensive.
Germany — Forschungszulage	Cash subsidy via tax credit	25% (large) / 35% (SMEs since March 2024)	Cap: EUR 10m eligible expenditure per claimant per year (was EUR 4m). Refundable if no tax liability.
Italy — R&D Credit (Credito d'imposta R&S)	Credit	10% basic research; 5% development; uplift to 15% for South + women + youth	Reduced from prior 12-50% rates. Combined with Italian Patent Box super-deduction.
Spain — R&D Credit (Deducción I+D+i)	Non-refundable credit + cash conversion option	25% (excess over prior 2-year average) + 42% on the excess; total cap 50% of CIT; cash-out at 80% of credit	Spanish CIT
Netherlands — WBSO	Payroll tax reduction	32% of first EUR 350k of qualifying R&D wages; 16% above (rates as updated 2025)	Reduces wage tax/social contributions of R&D employees. Stackable with Innovation Box.
Belgium — Partial Withholding Exemption	Payroll tax exemption	80% exemption on R&D wages for qualifying researchers	Stackable with Innovation Income Deduction.
Belgium — R&D Investment Deduction	Increased depreciation	15.5% investment deduction one-shot OR 22.5% spread	Choice; combined with patent income deduction.
Ireland — R&D Tax Credit	Refundable credit	30% (raised from 25% in FA 2023)	Cash refund possible over 3 years.
Poland — R&D Tax Relief	Super-deduction	100% deduction of qualifying costs; 200% for wage costs (loss possible)	Combined with IP Box.
Czech Republic — R&D Deduction	Deduction	100% uplift (200% total) of qualifying expenditure	Multi-year carryforward.
Romania — R&D Super-Deduction	Super-deduction	50% uplift (150% deduction)	Plus 16% credit for certain expenses.
Hungary — R&D Super-Deduction	Super-deduction	300% deduction of qualifying expenditure	Limited to entities with own R&D operations.
Slovakia — R&D Super-Deduction	Super-deduction	100% uplift (200% deduction)	Plus 25% increase year-over-year.
Portugal — SIFIDE II	Credit	32.5% basic + uplift to 50% for incremental expenditure	Specific innovation funds.
Norway — SkatteFUNN	Credit	19% SMEs; 19% large companies	Cap NOK 25m per project.
Sweden — R&D Payroll Relief	Payroll tax reduction	20% of R&D wages, cap SEK 1.5m/month	Plus general tax depreciation for R&D capex.
Denmark — R&D Super-Deduction	Deduction	108% of R&D expenses through 2025 (down from 130%); refundable for loss-makers up to DKK 25m	Negotiated annual extensions.
Finland — R&D Combined Deduction	Deduction	150% general R&D deduction + 50% R&D wage uplift (combined max 200%)	Plus payroll tax relief

3.2 Americas

Americas R&D regime matrix (Section 3.2 Americas country regime matrix)

Country	Mechanism	Headline rate	Notable
United States — §41 R&D Credit (Federal)	Non-refundable credit	20% regular method (over base period); 14% ASC simplified	Plus 6% payroll tax offset for QSBs. §174 capitalisation 5/15 years amortisation continues in 2025.
United States — State R&D Credits	Various	1.5% (NY)-15% (CA additional)	Stackable with federal
Canada — SR&ED	Refundable / non-refundable credit	35% refundable for CCPCs on first CAD 3m; 15% non-refundable above and for non-CCPCs	Provincial top-ups in ON, QC, BC, MB, NS, SK
Mexico — R&D Tax Credit	Credit	30% of incremental R&D expenditure	Limited budget; advance allocation required
Brazil — Lei do Bem	Super-deduction + accelerated depreciation	60-80% of R&D expenditure deductible (additional to 100% expense); accelerated depreciation of equipment; reduced IPI on imports	Lucro Real taxpayers only
Chile — R&D Credit (Ley 20.241)	Credit	35% of qualifying R&D, refundable	Annual cap UF 15,000
Argentina	Credit	Various sector schemes	Subject to currency and macro instability
Colombia	Deduction + credit	100% deduction + 25% credit on R&D investment	Annual cap

3.3 Asia-Pacific

Asia-Pacific R&D regime matrix (Section 3.3 Asia-Pacific country regime matrix)

Country	Mechanism	Headline rate	Notable
Australia — R&DTI (R&D Tax Incentive)	Refundable / non-refundable offset	48.5% refundable offset for aggregated turnover < AUD 20m; 38.5% non-refundable for larger	Loss-making refunds available
Japan — R&D Tax Credit	Credit	6-14% of R&D expenditure (base); plus incremental + open innovation uplifts up to 30%	SMEs higher base rate; multiple stackable categories
China — R&D Super-Deduction	Super-deduction	100% uplift (200% total deduction) for all industries (extended)	Permanent post-2021 expansion; manufacturing 200% historically maintained
India — §35 Income Tax Act	Super-deduction	150% in-house R&D (DSIR-approved); 100% outside R&D	Reduced from 200% by Finance Act 2017. Plus weighted deduction for scientific research.
Singapore — R&D Tax Deduction (§14C/§14D ITA)	Super-deduction	250% of qualifying R&D expenditure in Singapore (raised from 150% in Budget 2023)	Cash payout option for SMEs
South Korea — R&D Tax Credit	Credit	25-40% SMEs; 15-40% large (current vs base year)	Higher rates for "new growth engines" sectors
Taiwan — R&D Investment Tax Credit	Credit	15% of qualifying R&D, capped at 30% of CIT	Modified periodically
Indonesia — R&D Super-Deduction	Super-deduction	Up to 300% for specified R&D categories	Pre-approval required
Vietnam	Deduction	100% expensable; sector incentives separately	n/a
Thailand — Smart Visa / BOI	Various	Sector-specific	Combined with BOI incentives
Malaysia — R&D Approved Status	Deduction	100% in-house + special tax allowances	Pre-approval by MIDA

3.4 Africa

Africa R&D regime matrix (Section 3.4 Africa country regime matrix)

Country	Mechanism	Headline rate
South Africa — §11D R&D Deduction	Super-deduction	150% of qualifying R&D expenditure (pre-approval by DST required)
Egypt	Limited; sector schemes	n/a
Kenya	Limited; ICT and pharma sector incentives	n/a
Nigeria	20% R&D credit (subject to approval)	n/a

Section 4 — Computation walk-through (UK merged RDEC example)

For a UK accounting period beginning on or after 1 April 2024:

Step 1 — Qualifying activity test

• BEIS Guidelines on R&D qualifying activity test — Project seeks an advance in science or technology. Encounters scientific or technological uncertainty that a competent professional could not readily resolve. The advance must be a genuine advance in the relevant overall field, not just for the company. ([T1] BEIS Guidelines on R&D (formerly DSIT Guidelines))

Step 2 — Qualifying expenditure

• UK qualifying expenditure categories (CTA 2009 Part 13) — Categories: Staff costs (gross salary, employer NICs, pension); Externally provided workers (EPWs) — restricted to UK workers post-2024; Subcontracted R&D — restricted to UK subcontractors post-2024 (limited overseas exception); Consumable items (utilities, materials transformed in R&D); Software, data, cloud costs (new from 2023); Payments to qualifying bodies (universities, charities, scientific research orgs); Externally licensed R&D resources. Capital expenditure NOT eligible for R&D credit but RDA / R&D Allowances available separately. ([T1] CTA 2009 Part 13)

Step 3 — Compute the credit

• Merged RDEC formula — Credit = 20% × Qualifying R&D Expenditure. Credit is above-the-line (treated as taxable income). Net benefit (post-tax) = 20% × QRE × (1 - CT rate) ≈ 15% for main rate 25%. For ERIS (R&D-intensive loss-making SMEs): Uplifted loss = QRE × 186% (the 86% uplift); Surrendered loss credit = uplifted loss × 14.5% ≈ 27% net benefit. ([T1])

Step 4 — Filing

• UK filing mechanics and audit risk — Notification of intent to claim required within 6 months of period end if no claim in past 3 years (CT600L). Additional Information Form (AIF) required for all claims from 8 August 2023. Claim period: 2 years from end of accounting period. Audit risk: HMRC has expanded R&D enquiry capacity since 2022; expect requests for technical narratives, project documentation, time records. (unsure)

Section 5 — Computation walk-through (France CIR example)

Step 1 — Qualifying activity (CGI Art. 244 quater B)

• France qualifying activity — OECD Frascati criteria plus French specifics: Basic research, applied research, experimental development. Includes technological watch (max EUR 60k/yr) and patent expenses (deposit + maintenance + defence). ([T1] CGI Art. 244 quater B; OECD Frascati criteria)

Step 2 — Qualifying expenditure

• France qualifying expenditure categories — Researcher and technician wages (with 50% uplift for operating costs — "frais de fonctionnement"); Depreciation of R&D assets; Subcontracted R&D — to approved bodies only; capped at 2× internal R&D spend OR EUR 12m; Patent costs; Standardisation expenses; Young doctors' wages — doubled for first two years post-graduation. ([T1])

Step 3 — Compute the credit

• CIR computation formula — CIR = 30% × QRE up to EUR 100m + 5% × QRE above EUR 100m. For overseas territories: 50% on first slice. For young innovative companies: doubled. (unsure)

Step 4 — Use the credit

• France CIR usage rules — Offset against CIT due. Carry forward 3 years. Refund at end of year 4 if unused. Immediate refund for SMEs, JEI, young innovative companies, and loss-making companies in conciliation/safeguard. Pre-financing schemes (BPI France) advance the credit. (unsure)

Section 6 — US §174 capitalisation interaction

• US §174 capitalisation rules — TCJA 2017 amended IRC §174 effective for tax years beginning after 31 December 2021. Key effects: Domestic R&D expenditure must be capitalised and amortised over 5 years (mid-year convention). Foreign R&D expenditure must be capitalised and amortised over 15 years. Affects all R&D expenditure regardless of credit eligibility. §41 R&D credit base is independent of §174 capitalisation. Pending legislation has not restored immediate expensing as of mid-2025; bipartisan support exists but not enacted. ([T1])

[T2] Cash-flow timing of US R&D expenditure changed materially. R&D-intensive companies face significant Year 1 tax liabilities they did not have pre-TCJA. The §41 credit partially offsets but does not eliminate the cash impact.

Section 7 — Pillar Two interaction

• QRTC classification under Pillar Two — Qualified Refundable Tax Credits (QRTCs) — i.e., refundable within 4 years — are treated as income in GloBE Income (not as reductions of Covered Taxes). This means refundable credits do not push ETR below 15%. Non-refundable / non-qualified credits reduce Adjusted Covered Taxes, lowering ETR. Heavy reliance on R&D super-deductions in low-tax jurisdictions can trigger top-up tax. ([T1])

[T2] By regime:

• US §41 — non-refundable beyond the QSB payroll offset → reduces Covered Taxes → ETR impact
• UK ERIS — credit refundable in 4 years → treated as income → no ETR push
• Germany Forschungszulage — refundable → treated as income
• France CIR — refundable post-4-yr → treated as income → no ETR push if claimed timely
• Australia R&DTI refundable offset — treated as income
• Canada SR&ED refundable (CCPC) — treated as income
• Italy super-deduction — non-refundable reduction → reduces Covered Taxes
• Hungary 300% super-deduction — non-refundable → reduces Covered Taxes
• Netherlands WBSO — refundable via payroll withholding → treated as income

Section 8 — Edge cases and special rules

8.1 Subcontracted R&D and group transactions

• Subcontracted R&D and group transaction rules — Most regimes: Allow subcontracted R&D at restricted percentage of own R&D (commonly 65-80%). Restrict related-party subcontractor R&D to within OECD Modified Nexus Approach principles. The contracting party (the R&D commissioner) gets the credit; the contractor cannot also claim. (unsure)

8.2 Grants and subsidised R&D

• Grants and subsidised R&D offset rules — Most regimes: Reduce the credit base by the amount of grant/state-aid funding received for the same expenditure. Some allow combining (Italy partially). (unsure)

8.3 Foreign R&D performed abroad

• Foreign R&D performed abroad rules by country — UK (from 2024): generally exclude overseas R&D from claim. France: generally exclude unless within EEA + Norway / Iceland / Liechtenstein. US: include in §41 but §174 forces 15-year amortisation. Germany Forschungszulage: must be performed in Germany; EU sub-contracted possible under conditions. (unsure)

8.4 Software development

• Software development qualification by country — UK: covered if seeking advance in computer science. US: §41 software covered if functional/process improvement is the goal. France: software R&D yes; routine custom development no. (unsure)

8.5 Claim windows and amendments

Claim windows and amendments by country (unsure)

Country	Claim window
UK	2 years post-period-end
US	3 years from filing deadline; amended returns possible
France	3 years post-period-end
Germany	4 years generally
Canada SR&ED	18 months from period-end

8.6 Patent box stack

• R&D credit and patent box stacking by country — R&D credit and patent box are independent: France: CIR + IP Reduced Rate. UK: RDEC + Patent Box. Belgium: R&D investment deduction + Innovation Income Deduction. Italy: 110% iper-deduzione (now the "patent box replacement") combined with R&D credit. Netherlands: WBSO payroll relief + Innovation Box (the WBSO is partly a gateway condition for Innovation Box). (unsure)

Section 9 — Output specification

The reviewer brief must include:

1. R&D project inventory with technical narrative and Frascati test result per project
2. Qualifying expenditure schedule by category and project
3. Credit/super-deduction computation per regime claimed
4. Refundable vs non-refundable analysis and Pillar Two GloBE Income classification
5. §174 amortisation schedule (US claimants)
6. Filing deadline calendar per regime
7. Grant / state-aid offset schedule
8. Patent box interaction — confirm no double-counting; route IP income separately
9. Audit risk assessment — documentation status, prior enquiry history
10. Reviewer questions — open items flagged as [T2] or [T3]

Section 10 — Self-checks

• Frascati criteria applied per project — novelty, creativity, uncertainty, systematic, transferable
• Qualifying expenditure categories per regime, not assumed by analogy
• Subcontractor restrictions applied (UK 2024+ overseas restriction)
• §174 capitalisation modelled separately from §41 credit (US claimants)
• Refundability tested for Pillar Two QRTC classification
• Grant / state-aid offset applied to credit base
• Patent box income excluded from R&D credit base where claimed under patent box
• Filing deadline plotted with safety margin
• Additional Information Form / equivalent technical documentation prepared
• Output flags every [T2]/[T3] item for reviewer judgement

Section 11 — Prohibitions

• Prohibitions list — - Do not claim R&D credits for routine quality control, market research, social science research, or aesthetic/cosmetic activities — these fail the Frascati novelty test - Do not include grants in the qualifying expenditure base when the regime requires offset - Do not advise overseas subcontracting in the UK without confirming the limited 2024 exception applies - Do not stack R&D credit and patent box on the same IP income — Modified Nexus Approach requires separation - Do not treat the §41 US credit as solving the §174 capitalisation cash-flow timing problem — they are distinct - Do not ignore the OECD Pillar Two refundability classification — non-qualified credits push down the jurisdictional ETR (unsure)

Section 12 — Disclaimer

This skill and its outputs are provided for informational and computational purposes only and do not constitute tax, legal, or financial advice. R&D claims face significant audit scrutiny across virtually every jurisdiction. Every output must be reviewed and signed off by a credentialed practitioner (R&D specialist firms, Big 4 R&D advisory, or local equivalent) before any claim is filed.

The most up-to-date, verified version of this skill is maintained at openaccountants.com.